RepliCel Life Sciences (TSE:RP) has released an update.
Don't Miss Our Christmas Offers:
- Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
RepliCel Life Sciences has announced the sale of its assets and licensing of patent rights to 1456390 B.C. Ltd, a company controlled by RepliCel’s CEO Andrew Schutte. The deal is seen as the best path forward for maximizing shareholder return and commercializing the assets. The agreement includes an 8% royalty on gross profits from the commercialized products, promising a potential value increase for shareholders.
For further insights into TSE:RP stock, check out TipRanks’ Stock Analysis page.
